As of October 27, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of City Therapeutics, Inc. The largest reported stake is ARCH Venture Fund XII, L.P.'s, at 25.6%. 3 filings are on record since October 22, 2026 (Schedule 13D, October 26, 2026).
Sell to companies like City Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Viking Global Investors LP · Percent: 7% · SCHEDULE 13G
- · Holder: ARCH Venture Fund XII, L.P. · Percent: 25.6% · SCHEDULE 13D
- · Holder: Invus Public Equities, L.P. · Percent: 8.1% · SCHEDULE 13G
City Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2026-10-22. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 25.6% | 13,692,507 | SCHEDULE 13D, 2026-10-26 | 2026-10-19 |
| Invus Public Equities, L.P. | 8.1% | 4,302,772 | SCHEDULE 13G, 2026-10-22 | 2026-10-16 |
| Viking Global Investors LP | 7% | 3,727,005 | SCHEDULE 13G, 2026-10-26 | 2026-10-19 |
Holding shares or following this stake? See who's behind City Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on City Therapeutics, Inc. and the records around it.
City Therapeutics, Inc. elsewhere on the record
- IPO filing Oct 2026
- Who owns it
Companies that share a holder
- ARCH Venture Fund XII, L.P. also filed stake reports on 5 other companies: Parabilis Medicines, Inc. (Aug 2026), Seaport Therapeutics, Inc. (May 2026), Neumora Therapeutics, Inc. (Apr 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026), enGene Holdings Inc. (Aug 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026), Inhibrx Biosciences, Inc. (Aug 2026)
Watch City Therapeutics, Inc.
Get an email when City Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on City Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on City Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on City Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
ARCH Venture Fund XII, L.P.
AVF XII and the other Reporting Persons acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF XII and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-10-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-10-22 | Invus Public Equities, L.P. | 8.1% | SCHEDULE 13G |
| 2026-10-26 | Viking Global Investors LP | 7% | SCHEDULE 13G |
| 2026-10-26 | ARCH Venture Fund XII, L.P. | 25.6% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for City Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.